Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Brandon A Mahal, M.D.

Title
Institution
Department
Address
Phone
Fax
Profile Picture

Biography
Harvard Medical SchoolMD
Brigham and Women's HospitalInternshipInternal Medicine
Harvard Radiation Oncology ProgramResidencyRadiation Oncology
2015
Cum Laude (Harvard Medical School)
2018 - 2021
ASTRO-PCF Award to End Prostate Cancer
2019 - 2021
CDMRP Prostate Cancer Research Program (PCRP) Health Disparity Fellowship Award

Research
The research activities and funding listed below are automatically derived from NIH ExPORTER and other sources, which might result in incorrect or missing items. Faculty can login to make corrections and additions.
  1. PC180956 (Mahal) Jul 1, 2019 - Jul 1, 2021
    Department of Defense (DOD) Congressionally Directed Medical Research Programs (CDMRP)
    Genomic and Biological Risk Prediction of Aggressive and Lethal Prostate Cancer in African American Men
    Role: Prinicipal Investigator
  2. PCF 18YOUN12 (Career Development Award) (Mahal) Jul 1, 2018 - Jul 1, 2021
    Prostate Cancer Foundation/American Society for Radiation Oncology
    Integrative Genomics of Prostate Cancer Disparities
    Role: Principal Investigator

Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Tabrizi S, Alshalalfa M, Mahal BA, Davicioni E, Liu Y, Mouw KW, Feng F, Nguyen PL, Muralidhar V. Doublecortin expression in prostate adenocarcinoma and neuroendocrine tumors. Int J Radiat Oncol Biol Phys. 2020 Jun 22. PMID: 32585335.
    Citations:    
  2. Kishan AU, Romero T, Alshalalfa M, Liu Y, Tran PT, Nickols NG, Ye H, Sajed D, Rettig MB, Reiter RE, Garraway IP, Spratt DE, Freedland SJ, Zhao X, Li Z, Deek M, Livingstone J, Mahal BA, Nguyen PL, Feng FY, Den RB, Schaeffer EM, Lotan TL, Karnes RJ, Klein EA, Ross AE, Grogan T, Davicioni E, Elashoff D, Boutros PC, Weidhaas JB. Transcriptomic Heterogeneity of Gleason Grade Group 5 Prostate Cancer. Eur Urol. 2020 May 24. PMID: 32461072.
    Citations:    
  3. Jackson WC, Hartman HE, Dess RT, Birer SR, Soni PD, Hearn JWD, Reichert ZR, Kishan AU, Mahal BA, Zumsteg ZS, Efstathiou JA, Kaffenberger S, Morgan TM, Mehra R, Showalter TN, Krauss DA, Nguyen PL, Schipper MJ, Feng FY, Sandler HM, Hoskin PJ, Roach M, Spratt DE. Addition of Androgen-Deprivation Therapy or Brachytherapy Boost to External Beam Radiotherapy for Localized Prostate Cancer: A Network Meta-Analysis of Randomized Trials. J Clin Oncol. 2020 May 12; JCO1903217. PMID: 32396488.
    Citations:    
  4. Mahal BA. Editorial Comment. J Urol. 2020 Jul; 204(1):89. PMID: 32329649.
    Citations:    
  5. Dee EC, Fefer M, Hammoudeh L, Yu Z, Cantalino JM, Johnson TJ, O'Farrell DA, Bui AN, Muralidhar V, Mahal BA, Nguyen PL, LeBoeuf NR, Devlin PM. Surface applicator high-dose-rate fractionated brachytherapy for superficial cancers of the penis: A single-center case series and national database comparison. J Am Acad Dermatol. 2020 Apr 19. PMID: 32320768.
    Citations:    
  6. Zaorsky NG, Yu JB, McBride SM, Dess RT, Jackson WC, Mahal BA, Chen R, Choudhury A, Henry A, Syndikus I, Mitin T, Tree A, Kishan AU, Spratt DE. Prostate Cancer Radiotherapy Recommendations in Response to COVID-19. Adv Radiat Oncol. 2020 Apr 01. PMID: 32292839.
    Citations:    
  7. Tosoian JJ, Birer SR, Jeffrey Karnes R, Zhang J, Davicioni E, Klein EE, Freedland SJ, Weinmann S, Trock BJ, Dess RT, Zhao SG, Jackson WC, Yamoah K, Pra AD, Mahal BA, Morgan TM, Mehra R, Kaffenberger S, Salami SS, Kane C, Pollack A, Den RB, Berlin A, Schaeffer EM, Nguyen PL, Feng FY, Spratt DE. Performance of clinicopathologic models in men with high risk localized prostate cancer: impact of a 22-gene genomic classifier. Prostate Cancer Prostatic Dis. 2020 Mar 30. PMID: 32231245.
    Citations:    
  8. Dess RT, Sun Y, Jackson WC, Jairath NK, Kishan AU, Wallington DG, Mahal BA, Stish BJ, Zumsteg ZS, Den RB, Hall WA, Gharzai LA, Jaworski EM, Reichert ZR, Morgan TM, Mehra R, Schaeffer EM, Sartor O, Nguyen PL, Lee WR, Rosenthal SA, Michalski JM, Schipper MJ, Dignam JJ, Pisansky TM, Zietman AL, Sandler HM, Efstathiou JA, Feng FY, Shipley WU, Spratt DE. Association of Presalvage Radiotherapy PSA Levels After Prostatectomy With Outcomes of Long-term Antiandrogen Therapy in Men With Prostate Cancer. JAMA Oncol. 2020 Mar 26. PMID: 32215583.
    Citations:    
  9. Fletcher SA, Marchese M, Cole AP, Mahal BA, Friedlander DF, Krimphove M, Kilbridge KL, Lipsitz SR, Nguyen PL, Choueiri TK, Kibel AS, Trinh QD. Geographic Distribution of Racial Differences in Prostate Cancer Mortality. JAMA Netw Open. 2020 Mar 02; 3(3):e201839. PMID: 32232449.
    Citations:    
  10. Mahal AR, Chavez J, Yang DD, Kim DW, Cole AP, Hu JC, Trinh QD, Yu JB, Nguyen PL, Mahal BA. Early Impact of the Affordable Care Act and Medicaid Expansion on Racial and Socioeconomic Disparities in Cancer Care. Am J Clin Oncol. 2020 Mar; 43(3):163-167. PMID: 31904711.
    Citations:    
  11. Butler SS, Dee EC, Lamba N, Sha ST, Mahal BA, Whitbeck A, Makkar R, Wangoe J, Mouw KW, Nguyen PL, Muralidhar V. Validation of a subclassification for high-risk prostate cancer in a prospective cohort. Cancer. 2020 May 15; 126(10):2132-2138. PMID: 32073662.
    Citations:    
  12. Butler SS, Mahal BA. Reply to Obesity and aggressive prostate cancer and the golden rule: Do not do to others what you do not want done to yourself. Cancer. 2020 May 15; 126(10):2321-2322. PMID: 32022907.
    Citations:    
  13. Sanford NN, Giovannucci EL, Ahn C, Dee EC, Mahal BA. Obesity and younger versus older onset colorectal cancer in the United States, 1998-2017. J Gastrointest Oncol. 2020 Feb; 11(1):121-126. PMID: 32175114.
    Citations:    
  14. Pike LRG, Royce TJ, Mahal AR, Kim DW, Hwang WL, Mahal BA, Sanford NN. Outcomes of HPV-Associated Squamous Cell Carcinoma of the Head and Neck: Impact of Race and Socioeconomic Status. J Natl Compr Canc Netw. 2020 02; 18(2):177-184. PMID: 32023531.
    Citations:    
  15. Sha ST, Perni S, Muralidhar V, Mahal BA, Sanford NN, Nguyen PL, Dee EC. Trends, Quality, and Readability of Online Health Resources on Proton Radiation Therapy. Int J Radiat Oncol Biol Phys. 2020 May 01; 107(1):33-38. PMID: 31987973.
    Citations:    
  16. Fullerton ZH, Butler SS, Mahal BA, Muralidhar V, Schoenfeld JD, Tishler RB, Margalit DN. Short-term mortality risks among patients with oropharynx cancer by human papillomavirus status. Cancer. 2020 Apr 01; 126(7):1424-1433. PMID: 31930488.
    Citations:    
  17. Mahal BA, Alshalalfa M, Zhao SG, Beltran H, Chen WS, Chipidza F, Davicioni E, Karnes RJ, Ku SY, Lotan TL, Muralidhar V, Rebbeck TR, Schaeffer EM, Spratt DE, Feng FY, Nguyen PL. Genomic and clinical characterization of stromal infiltration markers in prostate cancer. Cancer. 2020 Apr 01; 126(7):1407-1412. PMID: 31905251.
    Citations:    
  18. Sanford NN, Sher DJ, Xu X, Ahn C, D'Amico AV, Aizer AA, Mahal BA. Alcohol Use Among Patients With Cancer and Survivors in the United States, 2000-2017. J Natl Compr Canc Netw. 2020 01; 18(1):69-79. PMID: 31910381.
    Citations:    
  19. Butler SS, Muralidhar V, Zhao SG, Sanford NN, Franco I, Fullerton ZH, Chavez J, D'Amico AV, Feng FY, Rebbeck TR, Nguyen PL, Mahal BA. Prostate cancer incidence across stage, NCCN risk groups, and age before and after USPSTF Grade D recommendations against prostate-specific antigen screening in 2012. Cancer. 2020 Feb 15; 126(4):717-724. PMID: 31794057.
    Citations:    
  20. Mahal AR, Johung KL, Mahal BA, Nguyen PL, Yu JB. An Update to Changing Patterns of Anal Carcinoma in the United States. Am J Clin Oncol. 2019 12; 42(12):887-897. PMID: 31651454.
    Citations:    
  21. Mahal BA. Fusion-guided biopsy to guide active surveillance in African-American men? BJU Int. 2019 11; 124(5):714-715. PMID: 31646756.
    Citations:    
  22. Sanford NN, Aguilera TA, Folkert MR, Ahn C, Mahal BA, Zeh H, Beg MS, Mansour J, Sher DJ. Sociodemographic Disparities in the Receipt of Adjuvant Chemotherapy Among Patients With Resected Stage I-III Pancreatic Adenocarcinoma. J Natl Compr Canc Netw. 2019 11 01; 17(11):1292-1300. PMID: 31693987.
    Citations:    
  23. Butler SS, Winkfield KM, Ahn C, Song Z, Dee EC, Mahal BA, Sanford NN. Racial Disparities in Patient-Reported Measures of Physician Cultural Competency Among Cancer Survivors in the United States. JAMA Oncol. 2019 Oct 31. PMID: 31670752.
    Citations:    
  24. Dess RT, Mahal BA, Spratt DE. Biology vs Access to Care-Relative Contribution to Racial Disparities in Prostate Cancer-In Reply. JAMA Oncol. 2019 Oct 31. PMID: 31670754.
    Citations:    
  25. Koch MJ, Mahal BAV, Hadzipasic M, Fehnel KP, Chapman PH, Loeffler JS, Orbach DB, Smith ER. Dynamic Changes in Arteriovenous Malformations (AVMs): Spontaneous Growth and Resolution of AVM-Associated Aneurysms in Two Pediatric Patients. Pediatr Neurosurg. 2019; 54(6):394-398. PMID: 31597140.
    Citations:    
  26. Muralidhar V, Mahal BA, Butler S, Lamba N, Yang DD, Leeman J, D'Amico AV, Nguyen PL, Trinh QD, Orio PF, King MT. Combined External Beam Radiation Therapy and Brachytherapy versus Radical Prostatectomy with Adjuvant Radiation Therapy for Gleason 9-10 Prostate Cancer. J Urol. 2019 11; 202(5):973-978. PMID: 31144590.
    Citations:    
  27. Butler SS, Loeb S, Cole AP, Zaslowe-Dude C, Muralidhar V, Kim DW, Schaeffer EM, Trinh QD, Nguyen PL, Mahal BA. United States trends in active surveillance or watchful waiting across patient socioeconomic status from 2010 to 2015. Prostate Cancer Prostatic Dis. 2020 03; 23(1):179-183. PMID: 31591454.
    Citations:    
  28. Lamba N, Mahal BA, Martinez R, Leland P, Shih HA. Radiation Therapy Pain Management: Prevalence of Symptoms and Effectiveness of Treatment Options. Clin J Oncol Nurs. 2019 10 01; 23(5):514-521. PMID: 31538974.
    Citations:    
  29. Sanford NN, Hwang WL, Pike LRG, Lam AC, Royce TJ, Mahal BA. Trimodality therapy for HPV-positive oropharyngeal cancer: A population-based study: Trimodality therapy for HPV+?OPC. Oral Oncol. 2019 11; 98:28-34. PMID: 31536843.
    Citations:    
  30. Spratt DE, Alshalalfa M, Fishbane N, Weiner AB, Mehra R, Mahal BA, Lehrer J, Liu Y, Zhao SG, Speers C, Morgan TM, Dicker AP, Freedland SJ, Karnes RJ, Weinmann S, Davicioni E, Ross AE, Den RB, Nguyen PL, Feng FY, Lotan TL, Chinnaiyan AM, Schaeffer EM. Transcriptomic Heterogeneity of Androgen Receptor Activity Defines a de novo low AR-Active Subclass in Treatment Naïve Primary Prostate Cancer. Clin Cancer Res. 2019 11 15; 25(22):6721-6730. PMID: 31515456.
    Citations:    
  31. Cole AP, Lu C, Krimphove MJ, Szymaniak J, Sun M, Fletcher SA, Lipsitz SR, Mahal BA, Nguyen PL, Choueiri TK, Kibel AS, Haider AH, Trinh QD. Comparing the Association Between Insurance and Mortality in Ovarian, Pancreatic, Lung, Colorectal, Prostate, and Breast Cancers. J Natl Compr Canc Netw. 2019 09 01; 17(9):1049-1058. PMID: 31487683.
    Citations:    
  32. Sanford NN, Sher DJ, Butler SS, Xu X, Ahn C, Aizer AA, Mahal BA. Prevalence of chronic pain among cancer survivors in the United States, 2010-2017. Cancer. 2019 12 01; 125(23):4310-4318. PMID: 31436323.
    Citations:    
  33. Muralidhar V, Nguyen PL, Mahal BA, Yang DD, Mouw KW, Rose BS, Beard CJ, Efstathiou JA, Martin NE, King MT, Orio PF. Practice Patterns and Outcomes Among Patients With N0M0 Prostate Cancer and a Very High Prostate-Specific Antigen Level. J Natl Compr Canc Netw. 2019 08 01; 17(8):941-948. PMID: 31390585.
    Citations:    
  34. Mahal BA, Catalano PJ, Haddad RI, Hanna GJ, Kass JI, Schoenfeld JD, Tishler RB, Margalit DN. Incidence and Demographic Burden of HPV-Associated Oropharyngeal Head and Neck Cancers in the United States. Cancer Epidemiol Biomarkers Prev. 2019 10; 28(10):1660-1667. PMID: 31358520.
    Citations:    
  35. Sanford NN, Mahal BA. The Use of e-Cigarettes in Patients With Cancer-A Double Shipwreck-In Reply. JAMA Oncol. 2019 Jul 25. PMID: 31343667.
    Citations:    
  36. Alimena S, Yang DD, Melamed A, Mahal BA, Worley MJ, Feldman S, Elias KM, Orio PF, Lee LJ, King M. Racial disparities in brachytherapy administration and survival in women with locally advanced cervical cancer. Gynecol Oncol. 2019 09; 154(3):595-601. PMID: 31292103.
    Citations:    
  37. Muralidhar V, Zhang J, Wang Q, Mahal BA, Butler SS, Spratt DE, Davicioni E, Sartor O, Feng FY, Mouw KW, Nguyen PL. Genomic Validation of 3-Tiered Clinical Subclassification of High-Risk Prostate Cancer. Int J Radiat Oncol Biol Phys. 2019 11 01; 105(3):621-627. PMID: 31271825.
    Citations:    
  38. Bitterman DS, Sanford NN, Niemierko A, Mahal BA, Qadan M, Ganguli S, Blaszkowsky LS, Zhu AX, Hong TS, Devlin PM, Goyal L, Wo JY. Patterns of Care and Outcomes of Definitive External Beam Radiotherapy and Radioembolization for Localized Hepatocellular Carcinoma: A Propensity Score-adjusted Analysis. Am J Clin Oncol. 2019 07; 42(7):564-572. PMID: 31166209.
    Citations:    
  39. Dess RT, Hartman HE, Mahal BA, Soni PD, Jackson WC, Cooperberg MR, Amling CL, Aronson WJ, Kane CJ, Terris MK, Zumsteg ZS, Butler S, Osborne JR, Morgan TM, Mehra R, Salami SS, Kishan AU, Wang C, Schaeffer EM, Roach M, Pisansky TM, Shipley WU, Freedland SJ, Sandler HM, Halabi S, Feng FY, Dignam JJ, Nguyen PL, Schipper MJ, Spratt DE. Association of Black Race With Prostate Cancer-Specific and Other-Cause Mortality. JAMA Oncol. 2019 07 01; 5(7):975-983. PMID: 31120534.
    Citations:    
  40. Mahal AR, Butler S, Franco I, Muralidhar V, Larios D, Pike LRG, Zhao SG, Sanford NN, Dess RT, Feng FY, D'Amico AV, Spratt DE, Yu JB, Nguyen PL, Rebbeck TR, Mahal BA. Conservative management of low-risk prostate cancer among young versus older men in the United States: Trends and outcomes from a novel national database. Cancer. 2019 10 01; 125(19):3338-3346. PMID: 31251398.
    Citations:    
  41. Alshalalfa M, Nguyen PL, Beltran H, Chen WS, Davicioni E, Zhao SG, Rebbeck TR, Schaeffer EM, Lotan TL, Feng FY, Mahal BA. Transcriptomic and Clinical Characterization of Neuropeptide Y Expression in Localized and Metastatic Prostate Cancer: Identification of Novel Prostate Cancer Subtype with Clinical Implications. Eur Urol Oncol. 2019 07; 2(4):405-412. PMID: 31164324.
    Citations:    
  42. Butler SS, Mahal BA, Lamba N, Mossanen M, Martin NE, Mouw KW, Nguyen PL, Muralidhar V. Use and early mortality outcomes of active surveillance in patients with intermediate-risk prostate cancer. Cancer. 2019 09 15; 125(18):3164-3171. PMID: 31150125.
    Citations:    
  43. Butler S, Muralidhar V, Chavez J, Fullerton Z, Mahal A, Nezolosky M, Vastola M, Zhao SG, D'Amico AV, Dess RT, Feng FY, King MT, Mouw KW, Spratt DE, Trinh QD, Nguyen PL, Rebbeck TR, Mahal BA. Active Surveillance for Low-Risk Prostate Cancer in Black Patients. N Engl J Med. 2019 05 23; 380(21):2070-2072. PMID: 31116925.
    Citations:    
  44. Sanford NN, Lam MB, Butler SS, Ahn C, Beg MS, Aizer AA, Mahal BA. Self-reported Reasons and Patterns of Noninsurance Among Cancer Survivors Before and After Implementation of the Affordable Care Act, 2000-2017. JAMA Oncol. 2019 May 15; e191973. PMID: 31091534.
    Citations:    
  45. Mahal BA, Huang FW. Racial Disparities in Low-Risk Prostate Cancer-Reply. JAMA. 2019 05 07; 321(17):1727-1728. PMID: 31063570.
    Citations:    
  46. Sanford NN, Sher DJ, Butler S, Xu X, Ahn C, D'Amico AV, Rebbeck T, Aizer AA, Mahal BA. Cancer Screening Patterns Among Current, Former, and Never Smokers in the United States, 2010-2015. JAMA Netw Open. 2019 05 03; 2(5):e193759. PMID: 31099863.
    Citations:    
  47. Sanford NN, Sher DJ, Ahn C, Aizer AA, Mahal BA. Prevalence and Nondisclosure of Complementary and Alternative Medicine Use in Patients With Cancer and Cancer Survivors in the United States. JAMA Oncol. 2019 May 01; 5(5):735-737. PMID: 30973579.
    Citations:    
  48. Chen WS, Alshalalfa M, Zhao SG, Liu Y, Mahal BA, Quigley DA, Wei T, Davicioni E, Rebbeck TR, Kantoff PW, Maher CA, Knudsen KE, Small EJ, Nguyen PL, Feng FY. Novel RB1-Loss Transcriptomic Signature Is Associated with Poor Clinical Outcomes across Cancer Types. Clin Cancer Res. 2019 Jul 15; 25(14):4290-4299. PMID: 31010837.
    Citations:    
  49. Jackson WC, Silva J, Hartman HE, Dess RT, Kishan AU, Beeler WH, Gharzai LA, Jaworski EM, Mehra R, Hearn JWD, Morgan TM, Salami SS, Cooperberg MR, Mahal BA, Soni PD, Kaffenberger S, Nguyen PL, Desai N, Feng FY, Zumsteg ZS, Spratt DE. Stereotactic Body Radiation Therapy for Localized Prostate Cancer: A Systematic Review and Meta-Analysis of Over 6,000 Patients Treated On Prospective Studies. Int J Radiat Oncol Biol Phys. 2019 07 15; 104(4):778-789. PMID: 30959121.
    Citations:    
  50. Krimphove MJ, Fletcher SA, Cole AP, Berg S, Sun M, Lipsitz SR, Mahal BA, Nguyen PL, Choueiri TK, Kibel AS, Kluth LA, Weissman JS, Trinh QD. Quality of Care in the Treatment of Localized Intermediate and High Risk Prostate Cancer at Minority Serving Hospitals. J Urol. 2019 04; 201(4):735-741. PMID: 30414956.
    Citations:    Fields:    
  51. Sanford NN, Sher DJ, Xu X, Aizer AA, Mahal BA. Trends in Smoking and e-Cigarette Use Among US Patients With Cancer, 2014-2017. JAMA Oncol. 2019 03 01; 5(3):426-428. PMID: 30763430.
    Citations:    
  52. Mahal BA, Butler S, Franco I, Spratt DE, Rebbeck TR, D'Amico AV, Nguyen PL. Use of Active Surveillance or Watchful Waiting for Low-Risk Prostate Cancer and Management Trends Across Risk Groups in the United States, 2010-2015. JAMA. 2019 Feb 19; 321(7):704-706. PMID: 30743264.
    Citations:    
  53. Mahal BA, Alshalalfa M, Spratt DE, Davicioni E, Zhao SG, Feng FY, Rebbeck TR, Nguyen PL, Huang FW. Prostate Cancer Genomic-risk Differences Between African-American and White Men Across Gleason Scores. Eur Urol. 2019 06; 75(6):1038-1040. PMID: 30683576.
    Citations:    Fields:    
  54. Cole AP, Fletcher SA, Berg S, Nabi J, Mahal BA, Sonpavde GP, Nguyen PL, Lipsitz SR, Sun M, Choueiri TK, Preston MA, Kibel AS, Trinh QD. Impact of tumor, treatment, and access on outcomes in bladder cancer: Can equal access overcome race-based differences in survival? Cancer. 2019 04 15; 125(8):1319-1329. PMID: 30633323.
    Citations:    Fields:    
  55. King MT, Yang DD, Muralidhar V, Mahal B, Butler S, Devlin PM, Lee LJ, Mouw KW, Martin NM, D'Amico AV, Nguyen PL, Orio PF. A comparative analysis of overall survival between high-dose-rate and low-dose-rate brachytherapy boosts for unfavorable-risk prostate cancer. Brachytherapy. 2019 Mar - Apr; 18(2):186-191. PMID: 30638912.
    Citations:    Fields:    
  56. Zhao SG, Chen WS, Das R, Chang SL, Tomlins SA, Chou J, Quigley DA, Dang HX, Barnard TJ, Mahal BA, Gibb EA, Liu Y, Davicioni E, Duska LR, Posadas EM, Jolly S, Spratt DE, Nguyen PL, Maher CA, Small EJ, Feng FY. Clinical and Genomic Implications of Luminal and Basal Subtypes Across Carcinomas. Clin Cancer Res. 2019 04 15; 25(8):2450-2457. PMID: 30573691.
    Citations:    Fields:    
  57. Mahal BA, Berman RA, Taplin ME, Huang FW. Prostate Cancer-Specific Mortality Across Gleason Scores in Black vs Nonblack Men. JAMA. 2018 12 18; 320(23):2479-2481. PMID: 30561471.
    Citations:    Fields:    Translation:Humans
  58. Yang DD, Mahal BA, Muralidhar V, Martin NE, Orio PF, Mouw KW, King MT, Choueiri TK, Trinh QD, Hoffman KE, Spratt DE, Feng FY, Nguyen PL. Androgen Deprivation Therapy and Overall Survival for Gleason 8 Versus Gleason 9-10 Prostate Cancer. Eur Urol. 2019 01; 75(1):35-41. PMID: 30554605.
    Citations:    
  59. Yuan J, Hu Z, Mahal BA, Zhao SD, Kensler KH, Pi J, Hu X, Zhang Y, Wang Y, Jiang J, Li C, Zhong X, Montone KT, Guan G, Tanyi JL, Fan Y, Xu X, Morgan MA, Long M, Zhang Y, Zhang R, Sood AK, Rebbeck TR, Dang CV, Zhang L. Integrated Analysis of Genetic Ancestry and Genomic Alterations across Cancers. Cancer Cell. 2018 10 08; 34(4):549-560.e9. PMID: 30300578.
    Citations:    Fields:    
  60. Yang DD, Muralidhar V, Mahal BA, Beard CJ, Mouw KW, Martin NE, Orio PF, King MT, Nguyen PL. Travel Distance as a Barrier to Receipt of Adjuvant Radiation Therapy After Radical Prostatectomy. Am J Clin Oncol. 2018 10; 41(10):953-959. PMID: 29045266.
    Citations:    Fields:    
  61. Pike LRG, Hwang WL, Royce TJ, Sanford NN, Mahal BA. HPV status predicts for improved survival following chemotherapy in metastatic squamous cell carcinoma of the oropharynx. Oral Oncol. 2018 11; 86:69-74. PMID: 30409322.
    Citations:    Fields:    
  62. Pike LRG, Bang A, Mahal BA, Taylor A, Krishnan M, Spektor A, Cagney DN, Aizer AA, Alexander BM, Rahma O, Balboni T, Ott PA, Hodi FS, Schoenfeld JD. The Impact of Radiation Therapy on Lymphocyte Count and Survival in Metastatic Cancer Patients Receiving PD-1 Immune Checkpoint Inhibitors. Int J Radiat Oncol Biol Phys. 2019 01 01; 103(1):142-151. PMID: 30227198.
    Citations:    Fields:    
  63. Sanford NN, Mahal BA, Royce TJ, Pike LRG, Hwang WL. Sex Disparity and Copy Number Alterations in Esophageal Squamous Cell Carcinoma. Clin Gastroenterol Hepatol. 2019 05; 17(6):1207-1209. PMID: 30120994.
    Citations:    Fields:    
  64. Hwang WL, Pike LRG, Royce TJ, Mahal BA, Loeffler JS. Safety of combining radiotherapy with immune-checkpoint inhibition. Nat Rev Clin Oncol. 2018 08; 15(8):477-494. PMID: 29872177.
    Citations: 1     Fields:    
  65. Mahal BA, Yang DD, Nguyen PL. Reply to John T. Leppert and James D. Brooks' Letter to the Editor re: Brandon A. Mahal, David D. Yang, Natalie Q. Wang, et al. Clinical and Genomic Characterization of Low-Prostate-specific Antigen, High-grade Prostate Cancer. Eur Urol 2018;74:146-54. Eur Urol. 2018 11; 74(5):e112-e113. PMID: 30029822.
    Citations:    Fields:    Translation:Humans
  66. Mahal BA, Chen MH, Renshaw AA, Loffredo MJ, Kantoff PW, D'Amico AV. Early Versus Delayed Initiation of Salvage Androgen Deprivation Therapy and Risk of Prostate Cancer-Specific Mortality. J Natl Compr Canc Netw. 2018 06; 16(6):727-734. PMID: 29891524.
    Citations:    Fields:    
  67. Dinh KT, Aizer AA, Muralidhar V, Mahal BA, Chen YW, Beard CJ, Choueiri TK, Hoffman KE, Hu JC, Martin NE, Sweeney CJ, Trinh QD, Nguyen PL. Increased Vulnerability to Poorer Cancer-Specific Outcomes Following Recent Divorce. Am J Med. 2018 05; 131(5):517-523. PMID: 29555248.
    Citations:    Fields:    
  68. Vastola ME, Yang DD, Muralidhar V, Mahal BA, Lathan CS, McGregor BA, Nguyen PL. Laboratory Eligibility Criteria as Potential Barriers to Participation by Black Men in Prostate Cancer Clinical Trials. JAMA Oncol. 2018 Mar 01; 4(3):413-414. PMID: 29423505.
    Citations:    Fields:    
  69. Mahal BA, Yang DD, Wang NQ, Alshalalfa M, Davicioni E, Choeurng V, Schaeffer EM, Ross AE, Spratt DE, Den RB, Martin NE, Mouw KW, Orio PF, Choueiri TK, Taplin ME, Trinh QD, Feng FY, Nguyen PL. Clinical and Genomic Characterization of Low-Prostate-specific Antigen, High-grade Prostate Cancer. Eur Urol. 2018 08; 74(2):146-154. PMID: 29478736.
    Citations:    Fields:    
  70. Mahal BA, Chen YW, Sethi RV, Padilla OA, Yang DD, Chavez J, Muralidhar V, Hu JC, Feng FY, Hoffman KE, Martin NE, Spratt DE, Yu JB, Orio PF, Nguyen PL. Travel distance and stereotactic body radiotherapy for localized prostate cancer. Cancer. 2018 03 15; 124(6):1141-1149. PMID: 29231964.
    Citations: 1     Fields:    
  71. Yang DD, Mahal BA, Muralidhar V, Vastola ME, Boldbaatar N, Labe SA, Nezolosky MD, Orio PF, King MT, Martin NE, Mouw KW, Trinh QD, Nguyen PL. Pathologic Outcomes of Gleason 6 Favorable Intermediate-Risk Prostate Cancer Treated With Radical Prostatectomy: Implications for Active Surveillance. Clin Genitourin Cancer. 2018 06; 16(3):226-234. PMID: 29196209.
    Citations:    Fields:    
  72. Mahal AR, Mahal BA, Nguyen PL, Yu JB. Prostate cancer outcomes for men aged younger than 65 years with Medicaid versus private insurance. Cancer. 2018 02 15; 124(4):752-759. PMID: 29084350.
    Citations: 1     Fields:    
  73. Yang DD, Muralidhar V, Mahal BA, Nguyen PL, Devlin PM, King MT, Orio PF. Lack of Apparent Survival Benefit With Use of Androgen Deprivation Therapy in Patients With High-risk Prostate Cancer Receiving Combined External Beam Radiation Therapy and Brachytherapy. Int J Radiat Oncol Biol Phys. 2018 01 01; 100(1):53-58. PMID: 29254781.
    Citations: 1     Fields:    Translation:Humans
  74. Yang DD, Mahal BA, Muralidhar V, Boldbaatar N, Labe SA, Nezolosky MD, Vastola ME, Beard CJ, Martin NE, Mouw KW, Orio PF, King MT, Nguyen PL. Receipt of definitive therapy in elderly patients with unfavorable-risk prostate cancer. Cancer. 2017 Dec 15; 123(24):4832-4840. PMID: 28832984.
    Citations:    Fields:    Translation:Humans
  75. Yang DD, Mahal BA, Muralidhar V, Nezolosky MD, Vastola ME, Labe SA, Boldbaatar N, King MT, Martin NE, Orio PF, Beard CJ, Hoffman KE, Trinh QD, Spratt DE, Feng FY, Nguyen PL. Risk of Upgrading and Upstaging Among 10 000 Patients with Gleason 3+4 Favorable Intermediate-risk Prostate Cancer. Eur Urol Focus. 2019 01; 5(1):69-76. PMID: 28753811.
    Citations: 1     Fields:    
  76. Yang DD, Muralidhar V, Mahal BA, Nezolosky MD, Labe SA, Vastola ME, Boldbaatar N, King MT, Martin NE, Orio PF, Choueiri TK, Trinh QD, Den RB, Spratt DE, Hoffman KE, Feng FY, Nguyen PL. Low rates of androgen deprivation therapy use with salvage radiation therapy in patients with prostate cancer after radical prostatectomy. Urol Oncol. 2017 09; 35(9):542.e25-542.e32. PMID: 28533151.
    Citations:    Fields:    Translation:Humans
  77. Mahal BA, Chen YW, Muralidhar V, Mahal AR, Choueiri TK, Hoffman KE, Hu JC, Sweeney CJ, Yu JB, Feng FY, Kim SP, Beard CJ, Martin NE, Trinh QD, Nguyen PL. Racial disparities in prostate cancer outcome among prostate-specific antigen screening eligible populations in the United States. Ann Oncol. 2017 05 01; 28(5):1098-1104. PMID: 28453693.
    Citations: 3     Fields:    Translation:Humans
  78. Yang DD, Muralidhar V, Mahal BA, Labe SA, Nezolosky MD, Vastola ME, King MT, Martin NE, Orio PF, Choueiri TK, Trinh QD, Spratt DE, Hoffman KE, Feng FY, Nguyen PL. National Trends and Predictors of Androgen Deprivation Therapy Use in Low-Risk Prostate Cancer. Int J Radiat Oncol Biol Phys. 2017 06 01; 98(2):338-343. PMID: 28463152.
    Citations:    Fields:    Translation:Humans
  79. Muralidhar V, Mahal BA, Rose BS, Chen YW, Nezolosky MD, Efstathiou JA, Beard CJ, Martin NE, Orio PF, Trinh QD, Choueiri TK, Sweeney CJ, Nguyen PL. Disparities in the Receipt of Local Treatment of Node-positive Prostate Cancer. Clin Genitourin Cancer. 2017 10; 15(5):563-569.e3. PMID: 28462857.
    Citations:    Fields:    Translation:Humans
  80. Mahal BA. Editorial Comment. J Urol. 2017 02; 197(2):348. PMID: 28346985.
    Citations:    Fields:    
  81. Chen YW, Muralidhar V, Mahal BA, Nezolosky MD, Beard CJ, Choueiri TK, Hoffman KE, Martin NE, Orio PF, Sweeney CJ, Feng FY, Trinh QD, Nguyen PL. Factors associated with the omission of androgen deprivation therapy in radiation-managed high-risk prostate cancer. Brachytherapy. 2016 Nov - Dec; 15(6):695-700. PMID: 27528590.
    Citations:    Fields:    Translation:Humans
  82. Markt SC, Lago-Hernandez CA, Miller RE, Mahal BA, Bernard B, Albiges L, Frazier LA, Beard CJ, Wright AA, Sweeney CJ. Insurance status and disparities in disease presentation, treatment, and outcomes for men with germ cell tumors. Cancer. 2016 Oct 15; 122(20):3127-3135. PMID: 27500561.
    Citations: 2     Fields:    Translation:Humans
  83. Mahal BA, Chen YW, Muralidhar V, Mahal AR, Choueiri TK, Hoffman KE, Hu JC, Sweeney CJ, Yu JB, Feng FY, Kim SP, Beard CJ, Martin NE, Trinh QD, Nguyen PL. National sociodemographic disparities in the treatment of high-risk prostate cancer: Do academic cancer centers perform better than community cancer centers? Cancer. 2016 Nov 15; 122(21):3371-3377. PMID: 27434225.
    Citations:    Fields:    Translation:Humans
  84. Dinh KT, Reznor G, Muralidhar V, Mahal BA, Nezolosky MD, Choueiri TK, Hoffman KE, Hu JC, Sweeney CJ, Trinh QD, Nguyen PL. Association of Androgen Deprivation Therapy With Depression in Localized Prostate Cancer. J Clin Oncol. 2016 06 01; 34(16):1905-12. PMID: 27069075.
    Citations: 9     Fields:    Translation:Humans
  85. Muralidhar V, Catalano PJ, Reznor G, Mahal BA, Choueiri TK, Sweeney CJ, Martin NE, Beard CJ, Chen YW, Nezolosky MD, Hoffman KE, Feng FY, Trinh QD, Nguyen PL. Variation in National Use of Long-Term ADT by Disease Aggressiveness Among Men With Unfavorable-Risk Prostate Cancer. J Natl Compr Canc Netw. 2016 04; 14(4):421-8. PMID: 27059190.
    Citations:    Fields:    Translation:Humans
  86. Spratt DE, Chen YW, Mahal BA, Osborne JR, Zhao SG, Morgan TM, Palapattu G, Feng FY, Nguyen PL. Individual Patient Data Analysis of Randomized Clinical Trials: Impact of Black Race on Castration-resistant Prostate Cancer Outcomes. Eur Urol Focus. 2016 Dec; 2(5):532-539. PMID: 28723519.
    Citations:    Fields:    
  87. Mahal BA, Chen YW, Efstathiou JA, Muralidhar V, Hoffman KE, Yu JB, Feng FY, Beard CJ, Martin NE, Orio PF, Nguyen PL. National trends and determinants of proton therapy use for prostate cancer: A National Cancer Data Base study. Cancer. 2016 05 15; 122(10):1505-12. PMID: 26970022.
    Citations: 5     Fields:    Translation:Humans
  88. Inverso G, Mahal BA, Aizer AA, Donoff RB, Chuang SK. Health Insurance Affects Head and Neck Cancer Treatment Patterns and Outcomes. J Oral Maxillofac Surg. 2016 Jun; 74(6):1241-7. PMID: 26851312.
    Citations: 2     Fields:    Translation:Humans
  89. Chao GF, Krishna N, Aizer AA, Dalela D, Hanske J, Li H, Meyer CP, Kim SP, Mahal BA, Reznor G, Schmid M, Choueiri TK, Nguyen PL, O'Leary M, Trinh QD. Asian Americans and prostate cancer: A nationwide population-based analysis. Urol Oncol. 2016 May; 34(5):233.e7-15. PMID: 26725248.
    Citations: 2     Fields:    Translation:Humans
  90. Chen YW, Mahal BA, Muralidhar V, Nezolosky M, Beard CJ, Den RB, Feng FY, Hoffman KE, Martin NE, Orio PF, Nguyen PL. Association Between Treatment at a High-Volume Facility and Improved Survival for Radiation-Treated Men With High-Risk Prostate Cancer. Int J Radiat Oncol Biol Phys. 2016 Mar 15; 94(4):683-90. PMID: 26972640.
    Citations: 8     Fields:    Translation:Humans
  91. Nezolosky MD, Dinh KT, Muralidhar V, Mahal BA, Chen YW, Beard CJ, Choueiri TK, Martin NE, Sweeney CJ, Trinh QD, Nguyen PL. Significant increase in prostatectomy and decrease in radiation for clinical T3 prostate cancer from 1998 to 2012. Urol Oncol. 2016 Feb; 34(2):57.e15-22. PMID: 26476663.
    Citations: 4     Fields:    Translation:Humans
  92. Sweeney C, Nakabayashi M, Regan M, Xie W, Hayes J, Keating N, Li S, Philipson T, Buyse M, Halabi S, Kantoff P, Sartor AO, Soule H, Mahal B. The Development of Intermediate Clinical Endpoints in Cancer of the Prostate (ICECaP). J Natl Cancer Inst. 2015 Dec; 107(12):djv261. PMID: 26409187.
    Citations: 4     Fields:    Translation:Humans
  93. Dinh KT, Muralidhar V, Mahal BA, Chen YW, Nezolosky MD, Beard CJ, Choueiri TK, Martin NE, Orio PF, Sweeney CJ, Trinh QD, Nguyen PL. Occult High-risk Disease in Clinically Low-risk Prostate Cancer with =50% Positive Biopsy Cores: Should National Guidelines Stop Calling Them Low Risk? Urology. 2016 Jan; 87:125-32. PMID: 26391387.
    Citations: 1     Fields:    Translation:Humans
  94. Mahal BA, Aizer AA, Efstathiou JA, Nguyen PL. Association of very low prostate-specific antigen levels with increased cancer-specific death in men with high-grade prostate cancer. Cancer. 2016 Jan 01; 122(1):78-83. PMID: 26371600.
    Citations: 6     Fields:    Translation:Humans
  95. Muralidhar V, Mahal BA, Nezolosky MD, Beard CJ, Feng FY, Martin NE, Efstathiou JA, Choueiri TK, Pomerantz MM, Sweeney CJ, Trinh QD, Vander Heiden MG, Nguyen PL. Association between very small tumour size and increased cancer-specific mortality after radical prostatectomy in lymph node-positive prostate cancer. BJU Int. 2016 Aug; 118(2):279-85. PMID: 26235660.
    Citations: 1     Fields:    Translation:Humans
  96. Mahal BA, Muralidhar V, Chen YW, Choueiri TK, Hoffman KE, Hu JC, Sweeney CJ, Yu JB, Feng FY, Trinh QD, Nguyen PL. Gleason score 5 + 3 = 8 prostate cancer: much more like Gleason score 9? BJU Int. 2016 Jul; 118(1):95-101. PMID: 26207642.
    Citations: 3     Fields:    Translation:Humans
  97. Muralidhar V, Mahal BA, Nguyen PL. Conditional cancer-specific mortality in T4, N1, or M1 prostate cancer: implications for long-term prognosis. Radiat Oncol. 2015 Jul 30; 10:155. PMID: 26220664.
    Citations: 2     Fields:    Translation:Humans
  98. Muralidhar V, Ziehr DR, Mahal BA, Chen YW, Nezolosky MD, Viswanathan VB, Choueiri TK, Sweeney CJ, Trinh QD, Nguyen PL. Association Between Older Age and Increasing Gleason Score. Clin Genitourin Cancer. 2015 Dec; 13(6):525-30.e1-3. PMID: 26119229.
    Citations: 2     Fields:    Translation:Humans
  99. Dinh KT, Mahal BA, Ziehr DR, Muralidhar V, Chen YW, Viswanathan VB, Nezolosky MD, Beard CJ, Choueiri TK, Martin NE, Orio PF, Sweeney CJ, Trinh QD, Nguyen PL. Risk of prostate cancer mortality in men with a history of prior cancer. BJU Int. 2016 06; 117(6B):E20-8. PMID: 25845283.
    Citations: 1     Fields:    Translation:Humans
  100. Muralidhar V, Dinh KT, Mahal BA, Ziehr DR, Chen YW, Viswanathan VB, Nezolosky MD, Choueiri TK, Hoffman KE, Hu JC, Sweeney CJ, Trinh QD, Nguyen PL. Differential post-prostatectomy cancer-specific survival of occult T3 vs. clinical T3 prostate cancer: Implications for managing patients upstaged on prostate magnetic resonance imaging. Urol Oncol. 2015 Jul; 33(7):330.e19-25. PMID: 25990612.
    Citations: 3     Fields:    Translation:Humans
  101. Mahal BA, Chen MH, Bennett CL, Kattan MW, Sartor O, Stein K, D'Amico AV, Nguyen PL. High PSA anxiety and low health literacy skills: drivers of early use of salvage ADT among men with biochemically recurrent prostate cancer after radiotherapy? Ann Oncol. 2015 Jul; 26(7):1390-5. PMID: 25926039.
    Citations: 1     Fields:    Translation:Humans
  102. Lago-Hernandez CA, Feldman H, O'Donnell E, Mahal BA, Perez V, Howard S, Rosenthal M, Cheng SC, Nguyen PL, Beard C, D'Amico AV, Sweeney CJ. A refined risk stratification scheme for clinical stage 1 NSGCT based on evaluation of both embryonal predominance and lymphovascular invasion. Ann Oncol. 2015 Jul; 26(7):1396-401. PMID: 25888612.
    Citations: 2     Fields:    Translation:HumansPHPublic Health
  103. Muralidhar V, Mahal BA, Ziehr DR, Chen YW, Nezolosky MD, Viswanathan VB, Beard CJ, Devlin PM, Martin NE, Orio PF, Nguyen PL. Shifting brachytherapy monotherapy case mix toward intermediate-risk prostate cancer. Brachytherapy. 2015 Jul-Aug; 14(4):511-6. PMID: 25887342.
    Citations: 1     Fields:    Translation:Humans
  104. Trinh QD, Nguyen PL, Leow JJ, Dalela D, Chao GF, Mahal BA, Nayak M, Schmid M, Choueiri TK, Aizer AA. Cancer-specific mortality of Asian Americans diagnosed with cancer: a nationwide population-based assessment. J Natl Cancer Inst. 2015 Jun; 107(6):djv054. PMID: 25794888.
    Citations: 14     Fields:    Translation:Humans
  105. Dinh KT, Mahal BA, Ziehr DR, Muralidhar V, Chen YW, Viswanathan VB, Nezolosky MD, Beard CJ, Choueiri TK, Martin NE, Orio PF, Sweeney CJ, Trinh QD, Nguyen PL. Incidence and Predictors of Upgrading and Up Staging among 10,000 Contemporary Patients with Low Risk Prostate Cancer. J Urol. 2015 Aug; 194(2):343-9. PMID: 25681290.
    Citations: 21     Fields:    Translation:Humans
  106. Mahal BA, Cooperberg MR, Aizer AA, Ziehr DR, Hyatt AS, Choueiri TK, Hu JC, Sweeney CJ, Beard CJ, D'Amico AV, Martin NE, Orio PF, Trinh QD, Nguyen PL. Who bears the greatest burden of aggressive treatment of indolent prostate cancer? Am J Med. 2015 Jun; 128(6):609-16. PMID: 25644324.
    Citations: 4     Fields:    Translation:Humans
  107. Inverso G, Mahal BA, Aizer AA, Donoff RB, Chau NG, Haddad RI. Marital status and head and neck cancer outcomes. Cancer. 2015 Apr 15; 121(8):1273-8. PMID: 25524565.
    Citations: 20     Fields:    Translation:Humans
  108. Mahal BA, Hoffman KE, Efstathiou JA, Nguyen PL. National trends in the recommendation of radiotherapy after prostatectomy for prostate cancer before and after the reporting of a survival benefit in March 2009. Clin Genitourin Cancer. 2015 Jun; 13(3):e167-72. PMID: 25554010.
    Citations: 2     Fields:    Translation:Humans
  109. Mahal BA, Inverso G, Aizer AA, Ziehr DR, Hyatt AS, Choueiri TK, Hoffman KE, Hu JC, Beard CJ, D'Amico AV, Martin NE, Orio PF, Trinh QD, Nguyen PL. Incidence and determinants of 1-month mortality after cancer-directed surgery. Ann Oncol. 2015 Feb; 26(2):399-406. PMID: 25430935.
    Citations: 2     Fields:    Translation:Humans
  110. Ziehr DR, Chen MH, Zhang D, Braccioforte MH, Moran BJ, Mahal BA, Hyatt AS, Basaria SS, Beard CJ, Beckman JA, Choueiri TK, D'Amico AV, Hoffman KE, Hu JC, Martin NE, Sweeney CJ, Trinh QD, Nguyen PL. Association of androgen-deprivation therapy with excess cardiac-specific mortality in men with prostate cancer. BJU Int. 2015 Sep; 116(3):358-65. PMID: 25124891.
    Citations: 13     Fields:    Translation:Humans
  111. Mahal BA, Chen MH, Bennett CL, Kattan MW, Sartor O, Stein K, D'Amico AV, Nguyen PL. The association between race and treatment regret among men with recurrent prostate cancer. Prostate Cancer Prostatic Dis. 2015 Mar; 18(1):38-42. PMID: 25348256.
    Citations: 3     Fields:    Translation:Humans
  112. Ziehr DR, Mahal BA, Aizer AA, Hyatt AS, Beard CJ, D Amico AV, Choueiri TK, Elfiky A, Lathan CS, Martin NE, Sweeney CJ, Trinh QD, Nguyen PL. Income inequality and treatment of African American men with high-risk prostate cancer. Urol Oncol. 2015 Jan; 33(1):18.e7-18.e13. PMID: 25306287.
    Citations: 8     Fields:    Translation:Humans
  113. Mahal BA, Inverso G, Aizer AA, Bruce Donoff R, Chuang SK. Impact of African-American race on presentation, treatment, and survival of head and neck cancer. Oral Oncol. 2014 Dec; 50(12):1177-81. PMID: 25261298.
    Citations: 1     Fields:    Translation:Humans
  114. Mahal BA, Aizer AA, Ziehr DR, Hyatt AS, Lago-Hernandez C, Chen YW, Choueiri TK, Hu JC, Sweeney CJ, Beard CJ, D'Amico AV, Martin NE, Trinh QD, Nguyen PL. The association between insurance status and prostate cancer outcomes: implications for the Affordable Care Act. Prostate Cancer Prostatic Dis. 2014 Sep; 17(3):273-9. PMID: 24980272.
    Citations: 7     Fields:    Translation:HumansPHPublic Health
  115. Parekh A, Chen MH, Graham P, Mahal BA, Hirsch AE, Nakabayashi M, Evan C, Kantoff PW, Martin NE, Nguyen PL. Role of androgen deprivation therapy in early salvage radiation among patients with prostate-specific antigen level of 0.5 or less. Clin Genitourin Cancer. 2015 Feb; 13(1):e1-6. PMID: 25103271.
    Citations: 5     Fields:    Translation:Humans
  116. Mahal BA, Aizer AA, Ziehr DR, Hyatt AS, Sammon JD, Schmid M, Choueiri TK, Hu JC, Sweeney CJ, Beard CJ, D'Amico AV, Martin NE, Kim SP, Trinh QD, Nguyen PL. Trends in disparate treatment of African American men with localized prostate cancer across National Comprehensive Cancer Network risk groups. Urology. 2014 Aug; 84(2):386-92. PMID: 24975710.
    Citations: 4     Fields:    Translation:Humans
  117. Mahal BA, Ziehr DR, Hyatt AS, Neubauer-Sugar EH, O'Farrell DA, O'Leary MP, Steele GS, Niedermayr TR, Beard CJ, Martin NE, Orio PF, D'Amico AV, Devlin PM, Nguyen PL. Use of a rectal spacer with low-dose-rate brachytherapy for treatment of prostate cancer in previously irradiated patients: Initial experience and short-term results. Brachytherapy. 2014 Sep-Oct; 13(5):442-9. PMID: 24880584.
    Citations: 4     Fields:    Translation:Humans
  118. Mahal BA, Ziehr DR, Aizer AA, Hyatt AS, Lago-Hernandez C, Choueiri TK, Elfiky AA, Hu JC, Sweeney CJ, Beard CJ, D'Amico AV, Martin NE, Kim SP, Lathan CS, Trinh QD, Nguyen PL. Racial disparities in an aging population: the relationship between age and race in the management of African American men with high-risk prostate cancer. J Geriatr Oncol. 2014 Oct 01; 5(4):352-8. PMID: 24862107.
    Citations: 3     Fields:    Translation:Humans
  119. Mahal BA, Ziehr DR, Aizer AA, Hyatt AS, Sammon JD, Schmid M, Choueiri TK, Hu JC, Sweeney CJ, Beard CJ, D'Amico AV, Martin NE, Lathan C, Kim SP, Trinh QD, Nguyen PL. Getting back to equal: The influence of insurance status on racial disparities in the treatment of African American men with high-risk prostate cancer. Urol Oncol. 2014 Nov; 32(8):1285-91. PMID: 24846344.
    Citations: 9     Fields:    Translation:Humans
  120. Mahal BA, Aizer AA, Ziehr DR, Hyatt AS, Choueiri TK, Hu JC, Hoffman KE, Sweeney CJ, Beard CJ, D'Amico AV, Martin NE, Kim SP, Trinh QD, Nguyen PL. Racial disparities in prostate cancer-specific mortality in men with low-risk prostate cancer. Clin Genitourin Cancer. 2014 Oct; 12(5):e189-95. PMID: 24861952.
    Citations: 10     Fields:    Translation:Humans
  121. Kumar V, Mahal BA. NGF - the TrkA to successful pain treatment. J Pain Res. 2012; 5:279-87. PMID: 23028238.
    Citations: 19     
  122. Mahal BA, Cohen JM, Allsop SA, Moore JB, Bhai SF, Inverso G, Dimitrakoff JD. The role of phenotyping in chronic prostatitis/chronic pelvic pain syndrome. Curr Urol Rep. 2011 Aug; 12(4):297-303. PMID: 21533747.
    Citations: 10     Fields:    Translation:Humans
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact feedbackcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Mahal's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (227)
Explore
_
Co-Authors (97)
Explore
_
Similar People (60)
Explore
_
Same Department 
Explore
_
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.